Trials / Completed
CompletedNCT03613636
Evaluation of Pathogenesis and Diagnosis of Mycoplasma Pneumoniae Community-acquired Pneumonia (CAP)
The Role of Adaptive Immune Responses to Mycoplasma Pneumoniae in Pathogenesis and Diagnosis of Community-acquired Pneumonia (CAP) in Children: an Observational Single-center Study (myCAP Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 490 (actual)
- Sponsor
- University Children's Hospital, Zurich · Academic / Other
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Accepted
Summary
To investigate the Mycoplasma pneumoniae-specific circulating antibody-secreting cell (ASC) response and Mycoplasma pneumoniae-specific interferon (INF)-γ-secreting T cell response, along with polymerase chain reaction (PCR) and serology, in a cohort of children with community-acquired pneumonia (CAP) and controls.
Conditions
- Childhood Pneumonia
- Mycoplasma Pneumonia
- Antibody-secreting Cells
- Enzyme-linked Immunospot (ELISpot)
- Diagnosis
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Enzyme-linked immunospot (ELISpot) assay [Blood] | The ASC ELISpot will be developed based on the improved methods recently described \[Nat Protoc 2013;8:1073-87\]. This protocol allows rapid (6-8 h) detection of specific ASCs in small volumes (1-2 ml) of blood. M. pneumoniae protein P1 (50 μl/ml) will be used as antigen. The optimal concentration of coating antigen will be assessed in advance in two-fold serial dilutions for clear spot definition. The M. pneumoniae-specific T cell ELISpot will be developed based on methods recently described \[Nat Protoc 2009;4:461-9\]. |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2020-10-31
- Completion
- 2020-10-31
- First posted
- 2018-08-03
- Last updated
- 2024-02-22
Source: ClinicalTrials.gov record NCT03613636. Inclusion in this directory is not an endorsement.